These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37646826)

  • 1. Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Cancer Immunol Immunother; 2023 Nov; 72(11):3755-3764. PubMed ID: 37646826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Cancer Immunol Immunother; 2021 Apr; 70(4):1063-1074. PubMed ID: 33113005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
    He J; Pan Y; Guo Y; Li B; Tang Y
    J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC).
    Mildner FO; Sykora MM; Hackl H; Amann A; Zelger B; Sprung S; Buch ML; Nocera F; Moser P; Maier H; Augustin F; Manzl C; Kocher F; Pircher A; Lindenmann J; Mykoliuk I; Raftopoulou S; Kargl J; Wolf D; Sopper S; Gamerith G
    Lung Cancer; 2024 Oct; 196():107955. PubMed ID: 39306924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
    Li Y; Liu H; Zhao Y; Yue D; Chen C; Li C; Zhang Z; Wang C
    Thorac Cancer; 2021 Oct; 12(20):2698-2709. PubMed ID: 34423566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients.
    Ancın B; Özercan MM; Yılmaz YM; Uysal S; Kumbasar U; Sarıbaş Z; Dikmen E; Doğan R; Demircin M
    Turk J Med Sci; 2022 Aug; 52(4):1050-1057. PubMed ID: 36326416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
    Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y
    Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma sPD-L1 and VEGF levels are associated with the prognosis of NSCLC patients treated with combination immunotherapy.
    Dong C; Hui K; Gu J; Wang M; Hu C; Jiang X
    Anticancer Drugs; 2024 Jun; 35(5):418-425. PubMed ID: 38386011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
    Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].
    Hang Q; Ying H; Cheng G; Yang S; Jin J; Chen Y; Chen Q; Jiang Y; Zhao Q; Fang M; Chen M; Lai X
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):837-844. PubMed ID: 33070512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients.
    Chmielewska I; Grenda A; Krawczyk P; Frąk M; Kuźnar Kamińska B; Mitura W; Milanowski J
    Cancer Immunol Immunother; 2023 Dec; 72(12):4169-4177. PubMed ID: 37816808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
    Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
    J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
    Himuro H; Nakahara Y; Igarashi Y; Kouro T; Higashijima N; Matsuo N; Murakami S; Wei F; Horaguchi S; Tsuji K; Mano Y; Saito H; Azuma K; Sasada T
    Cancer Immunol Immunother; 2023 Aug; 72(8):2829-2840. PubMed ID: 37188764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer.
    Qu Y; Wang H; Liu H; Sun X; Li J; Yu H
    Biomed Res Int; 2021; 2021():8811751. PubMed ID: 33987445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
    Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
    Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
    Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer.
    Yang L; Zhang W; Sun J; Yang G; Cai S; Sun F; Xing L; Sun X
    Cancer Immunol Immunother; 2023 Jul; 72(7):2015-2027. PubMed ID: 36738309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis.
    Wang Y; He H
    Immunotherapy; 2022 Aug; 14(12):945-956. PubMed ID: 35822688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.